CLINICAL_TRIALS
trial_result
· 2018-03-29
Clinical Trial Update: AUY922 for Advanced ALK-positive NSCLC [Phase 2]
Summary
Phase 2 trial update reporting results for AUY922 (ganetespib) in advanced ALK-positive non-small cell lung cancer; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Massachusetts General Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-03-29